THE WOODLANDS, Texas--(BUSINESS WIRE)--
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company
developing personalized immunotherapies for autoimmune disorders,
including multiple sclerosis (MS) and neuromyelitis optica (NMO), today
announced its partnership with the National Multiple Sclerosis Society,
Lone Star Chapter, as a sponsor of the nonprofit’s annual Houston area Walk
MS fundraisers for the fourth consecutive year.
Opexa is supporting the Walk MS program for the Society’s Texas
Lone Star Chapter, which serves more than 68,000 individuals affected by
MS in Texas. The Houston area fundraisers take place throughout October
and November and consist of four local walks, including in The
Woodlands, the location of Opexa’s corporate headquarters.
“Opexa is proud to be a partner of the National MS Society’s Houston
area Walk MS events,” stated Neil K. Warma, Opexa's President and
Chief Executive Officer. “We are committed to helping the Society
support critical programs and services to improve the quality of life
for people affected by MS. We are dedicated to developing a personalized
therapy for Secondary Progressive MS, and these events offer the unique
opportunity for those of us in the Company to meet people living with MS
and their families, which provides us with tremendous motivation.”
Walk MS is the rallying point of the MS Movement, a community
coming together to raise funds and celebrate hope for the future for the
more than 2.3 million people living with MS worldwide. In 2013, Walk
MS events throughout the South Central Chapter territory, which
includes The Lone Star Chapter, attracted more than 25,000 participants
and raised more than $3.2 million for the National Multiple Sclerosis
Society. Nationally, since 1988, Walk MS has raised more
than $770 million to support life changing programs and cutting-edge
research and development of new therapies.
Opexa would like to remind Walk MS participants that there will
be a donation drop-off day for the fundraisers at the Company’s offices
in The Woodlands on Wednesday, October 22nd from
11:00 am -1:00 pm CT. Phone 281-775-0609 for more information.
About Opexa
Opexa is a biopharmaceutical company developing personalized
immunotherapies with the potential to treat major illnesses, including
multiple sclerosis (MS) as well as other autoimmune diseases, such as
neuromyelitis optica (NMO). These therapies are based on Opexa’s
proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®,
is a personalized T-cell immunotherapy that is in a Phase IIb clinical
development program (the Abili-T trial) for the treatment of Secondary
Progressive MS. Tcelna is derived from T-cells isolated from the
patient’s peripheral blood, expanded ex vivo, and reintroduced
into the patients via subcutaneous injections. This process triggers a
potent immune response against specific subsets of autoreactive T-cells
known to attack myelin. Opexa’s mission is to lead the field of
Precision Immunotherapy® by aligning the interests of
patients, employees and shareholders.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.
Forward-Looking Statements
Statements contained in this release, other than statements of
historical fact, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The
words "expects," "believes," "may," "intends," "potential" and similar
expressions are intended to identify forward-looking statements. These
forward-looking statements do not constitute guarantees of future
performance. Investors are cautioned that forward-looking statements,
including without limitation statements regarding the safety, efficacy
and projected development timeline of drug candidates such as Tcelna®
and OPX-212 constitute forward-looking statements. These
forward-looking statements are based upon our current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as
a result of various risks and uncertainties, which include without
limitation our ability to raise additional capital to continue our
development programs, our ability to successfully develop potential
products such as Tcelna, our ability to obtain, maintain and protect
intellectual property rights (including for Tcelna and future pipeline
candidates such as OPX-212), as well as other risks associated with the
process of discovering, developing and commercializing drug candidates
that are safe and effective for use as human therapeutics. These and
other risks are described in detail in our SEC filings, including our
Annual Report on Form 10-K for the year ended December 31, 2013 and our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. All
forward-looking statements contained in this release speak only as of
the date on which they were first made by us, and we undertake no
obligation to update such statements to reflect events that occur or
circumstances that exist after such date.
Source: Opexa Therapeutics, Inc.